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ABSTRACT: Pharmacological modulation of cannabinoid type 2
receptor (CB2R) holds promise for the treatment of numerous
conditions, including inflammatory diseases, autoimmune disorders,
pain, and cancer. Despite the significance of this receptor, researchers
lack reliable tools to address questions concerning the expression and
complex mechanism of CB2R signaling, especially in cell-type and
tissue-dependent contexts. Herein, we report for the first time a
versatile ligand platform for the modular design of a collection of
highly specific CB2R fluorescent probes, used successfully across
applications, species, and cell types. These include flow cytometry of
endogenously expressing cells, real-time confocal microscopy of
mouse splenocytes and human macrophages, as well as FRET-based
kinetic and equilibrium binding assays. High CB2R specificity was
demonstrated by competition experiments in living cells expressing CB2R at native levels. The probes were effectively applied to
FACS analysis of microglial cells derived from a mouse model relevant to Alzheimer’s disease.
■ INTRODUCTION
There is currently great interest in the endocannabinoid
system (eCB system) and associated signaling pathways in
relation to the chemistry of life as well as in the context of
developing new therapies. The eCB system is a complex lipid
signaling network found in all vertebrates and consists of
cannabinoid receptors (CBRs), their endogenous ligands
(endocannabinoids), enzymes involved in ligand biosynthesis
and degradation, as well as endocannabinoid transporters.1
Cannabinoid type 1 and 2 receptors (CB1R and CB2R) are
class A G-protein-coupled receptors (GPCRs) and have been
shown to be involved in numerous physiological processes
and disease states.2−4 They share 44% overall and 68%
homology in the ligand-binding domain.3 Notably, CB1R is
the most abundant GPCR in the central nervous system
(CNS) and mediates the psychotropic effects associated with
Cannabis consumption mainly through the action of (−)-Δ9-
trans-tetrahydrocannabinol ((−)-Δ9-THC).5 CB2R is pre-
dominantly expressed in the periphery, largely by cells of the
immune system,6,7 and is considered a highly promising
target for the treatment of tissue injury and inflammation,8,9
as well as neurodegenerative diseases such as Alzheimer’s
disease (AD) and multiple sclerosis.10,11 Although several
structurally distinct CB2R agonists have shown promising
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effects in animal disease models, none has so far succeeded in
the clinic,12 stressing the need for better fundamental
understanding of CB2R chemistry, biology, and medicine.
10
The ability to address important questions is hampered by
the lack of reliable biological tools such as receptor-specific
antibodies,13−15 and the highly inducible nature of CB2R
expression as a function of disease state16−18 further
complicates its biochemical and biophysical analysis.
Small-molecule-based probes will help to interrogate CB2R
function, mechanism of action, biased signaling, expression
levels, and protein distribution in health and disease.19 Of
particular interest are fluorescent probes, which allow for real-
time monitoring of ligand−receptor interactions and protein
visualization with high spatiotemporal precision.20−22 Several
fluorescent ligands targeting CB2R have been reported.
23−35
However, in our collective experience, the published probes
perform less than optimally as judged by at least one of the
following criteria: modularity of design for multiple
applications, selectivity over CB1R, affinity and specificity
for CB2R, photophysical properties, and applicability across
species, techniques, and cell types. Furthermore, bifunctional
probes that require additional manipulations prior to imaging
are often incompatible with live cells.36,37
Recently, we reported the synthesis of HU-308-derived38
primary amine 1 (Figure 1), which was linked via R2 to
residues such as alkynes, diazirines, azobenzene photo-
switches, and 7-nitrobenzofurazan (NBD) dye (2). These
were evaluated in limited in vitro pharmacology (CB2R and
CB1R Ki, cAMP). However, the preliminary studies were
largely synthetic in nature and did not assess 2 as a
fluorescent probe. Herein, we report the modular synthesis
and in-depth pharmacological evaluation of a series of CB2R
specific, high-affinity fluorescent probes. We also document
their in situ application and validation in flow cytometry and
real-time confocal microscopy of both living human and
murine cells. Additionally, these probes proved effective in
time-resolved fluorescence resonance energy transfer (TR-
FRET)-based assays, allowing for determination of both
binding affinities and kinetic parameters of CB2R ligands
without radiolabeled material. Finally, the probes are
successfully applied to fluorescence-activated cell sorting
(FACS) analysis of cells from a mouse model of Alzheimer’s
disease.
■ RESULTS AND DISCUSSION
Modular Probe Design and in vitro Pharmacology.
With a high-affinity recognition element, such as 1,39 as a
starting point, choices of the exit vector and linker-type for
fluorophore attachment are the main challenges to ensure
high probe affinity and selectivity.40,41 Our preliminary
synthetic studies with 2 suggested a strategy for a family of
Figure 1. Modular design of CB2R fluorescent probes. Attachment of fluorescent dyes to amine building block 1 via short linkers gives rise to
CB2R-selective fluorescent probes with bespoke photophysical properties.
Table 1. In Vitro Pharmacological Assessment of CB2R Fluorescent Probes
a
Ki [nM] EC50 [nM]
compd dye hCB2R hCB1R mCB2R hKi ratio (CB1R/CB2R) hCB2R hCB1R mCB2R EC50 ratio (CB1R/CB2R)
2 NBD 4.2 >10 000 n.d.b >2381 n.d. n.d. n.d. n.d.
3a DY-480XL 99 4031 1986 41 >10 000 >10 000 >10 000 n.d.
3b DY-480XL 21 2378 1459 113 171 (150) >10 000 118 (115) >58
4 Alexa647 2565 >10 000 >10 000 >3.9 25 (109) 2152 (138) 370 (123) 86
5 Alexa488 268 >10 000 1 204 >37 n.d. n.d. n.d. n.d.
6 AttoThio12 4.7 1075 1.1 228 5.6 (74) >10 000 17 (73) >1785
aBinding affinity (Ki) values were determined by a radioligand binding assay utilizing radioligand [
3H]-CP55,940 and membrane preparations from
CHO cells overexpressing hCB1R, hCB2R, or mCB2R. Forskolin-stimulated cAMP (EC50) levels were measured using cells stably expressing
hCB2R, mCB2R, or hCB1R. Figures in parentheses correspond to efficacy expressed in % relative to 1 μM CP55,940.
bn.d. = not determined.
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fluorescent probes.42 Consequently, herein we report a series
of probes 3a−6 in which the fluorescent dye was varied
(Figure 1; for synthetic details, see the Supporting
Information (SI)). Fluorophores DY-480XL,43 Alexa647,44
Alexa488,45 and AttoThio1246 were chosen for their large
Stokes shift, red-shifted absorption and emission maxima with
high extinction coefficient, suitability for FRET, and potential
for ultra-high-resolution microscopy, respectively (for fluo-
rescence spectra, see SI Figure S1 and Table S1). We focused
on high-affinity azides 3b, 5, and 6, as well as, for
comparison, hydrocarbon analogs 3a and 4.
All fluorescent probes were subjected to in vitro
pharmacological profiling in order to evaluate their affinity
for CB2R and selectivity over CB1R (Table 1). Radioligand
competition binding studies were performed with tritiated
CP55,940 and membrane preparations of Chinese hamster
ovary (CHO) cells overexpressing human (hCB2R) or mouse
CB2R (mCB2R), or human CB1R (hCB1R). Compounds 3a,
3b, 5, and 6 showed high to excellent affinity to hCB2R,
exhibiting Ki values of 99, 21, 268, and 4.7 nM, respectively,
as well as good selectivity over hCB1R, with hCB1R/hCB2R
Ki ratios of 41, 113, >37, and 228, respectively.
47 The
presence of the terminal azide in 3b led to significantly higher
binding affinity for hCB2R as well as boosted selectivity over
hCB1R when compared to 3a. To the best of our knowledge,
the high selectivity of 3b and 6 for hCB2R over hCB1R is
unprecedented for fluorescent CB2R agonists, as discussed
below.
In 2019 and 2020, X-ray and cryo-electron microscopy
(cryo-EM) structures of antagonist- and agonist-bound CB2R
were reported.48−50 We used the X-ray crystal structure of
CB2R in its active state, determined in complex with agonist
WIN55,212,49 in docking experiments of DY-480XL probe
3b. The docking pose suggests that the fluorophore is
positioned in the extracellular space (Figure 2). In addition,
the azide of agonist 3b is involved in a favorable H-bond
with the CαH of Leu191. This may explain the higher affinity
of 3b as well as of 6 as compared to probe 3a carrying a
hydrogen atom instead of an azide at the terminus of the
alkyl side chain.
In functional studies, probe 3b showed agonist activity with
high efficacy (hCB2R cAMP EC50 = 171 nM, %eff = 150). A
comparable value for 3b, EC50 = 133 nM, was obtained in a
[35S]GTP-γ-S G-protein activation study using hCB2R
expressed in E. coli membranes (see SI Figure S2).
AttoThio12 probe 6 performed best in terms of affinity and
selectivity, displaying single-digit nanomolar hCB2R Ki as well
as 228-fold selectivity over hCB1R. In a cAMP assay,
51 6
displayed lower efficacy, showing a trend toward partial
agonism, and exclusively activated hCB2R over hCB1R:
hCB2R cAMP EC50 = 5.6 nM, hCB1R/hCB2R EC50 ratio
>1785. The weaker affinity of Alexa647 probe 4 to hCB2R
was unexpected, as it showed excellent CB2R specificity in
live-cell flow cytometry at concentrations below its apparent
Ki, as discussed below. In forskolin-stimulated cAMP assay, 4
exhibited potent agonism: hCB2R cAMP EC50 = 25 nM and
hCB1R/hCB2R EC50 ratio = 86.
To check for interspecies differences that could com-
promise transferability of preclinical data from animal models
to humans, binding studies were also performed with
mCB2R.
52 Probes 3a, 3b, 4, and 5 showed reduced binding
affinities to mCB2R compared to hCB2R, while 6 retained
single-digit nanomolar affinity to mCB2R, Ki = 1.1 nM. To
identify potential off-targets, compound 3b was screened
against a customized panel of 50 representative proteins,
including classical cannabinoid targets PPARγ and 5-HT1A.
53
In this assay, 3b exhibited very clean profile, showing only a
weak interaction with prostaglandin F receptor, which was
considered not relevant due to the high test concentration of
10 μM (see SI Table S2).
In summary, modular fluorophore attachment to linchpin 1
gave rise to a series of high-affinity CB2R-selective fluorescent
probes with bespoke photophysical properties. With several
high-affinity and selective CB2R fluorescent probes in hand,
we set out to interrogate their utility in biological
applications, with a strong focus on validation across various
laboratories and cell lines.
TR-FRET-Based Determination of Equilibrium and
Kinetic Binding Parameters: Radioligand-Free Assay.
Radioligands are ubiquitously used to study GPCR expression
as well as ligand binding affinities and kinetics.54 Safety
concerns, radioactive waste management, and, in the case of
filtration assays, the need for iterative washing steps limit the
applicability of radioligand-based assays for high-throughput
screening (HTS). Fluorescent probes are devoid of such
drawbacks and thus, in conjunction with FRET-based assays,
offer attractive solutions toward the development of high-
throughput equilibrium binding assays.55−59 In addition, time-
resolved methods (TR-FRET) enable studying ligand binding
kinetics, one of the key determinants of drug efficacy and
safety.60−65
Toward this end, human embryonic kidney (HEK293T-
Rex) cells overexpressing SNAP-tagged hCB2R were labeled
with a SNAP-Lumi4-Tb FRET-donor (see SI). Laser
excitation (337 nm) of this donor initiates energy transfer
(FRET) to a proximal fluorescent probe acceptor. Membrane
preparations of the derived cells were used to determine the
binding kinetics of the most promising fluoroprobes, 3b and
6, using the TR-FRET technique by measuring the observed
association rates kobs at various ligand concentrations, as
shown for 3b in Figure 3A (for analogous results with 6, see
SI). The observed rates of association were found to be
linearly correlated to the fluorescent probe concentration, as
shown in Figure 3B for 3b. Kinetic rate parameters koff and
kon for the two probes were calculated by globally fitting
Figure 2. CB2R docking studies. Probe 3b was docked into active-
state CB2R crystal structure (PDB: 6PTO).
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association time courses. The ratio of these parameters, koff/
kon, is equivalent to the ligand dissociation constant Kd.
Saturation binding analysis provided additional means for
determining binding constants as shown for 3b in Figure 3C.
Reassuringly, the two sets of Kd values were in good
agreement: 35 vs 36 nM for 3b and 18 vs 13 nM for 6, as
shown in Table 2.
Additionally, good correlation was found between Ki values
for 3b, 4, and 6 determined independently by FRET and by
radioligand studies. Together with microscopy data showing
membrane localization of SNAP-hCB2R, this correlation
justified the use of SNAP-tagged hCB2R for further studies
(see SI Figures S4 and S5). Additional control experiments
were performed in order to validate the assay. The specificity
of association between 3b and CB2R was demonstrated by
experiments employing membrane preparations of cells
overexpressing SNAP-tagged β2 adrenergic receptor (Figure
S6A−C). The TR-FRET emission ratio was also completely
abolished by addition of unlabeled HU-308, which highlights
successful FRET between receptor and probe as well as full
reversibility of tracer binding (Figure S6D).
We next set out to validate 3b and 6 as fluorescent
alternatives to radioligand tracers. Binding affinities for
established CB2R-selective agonist HU-308 and inverse
agonist SR14452866 were determined in competition experi-
ments with fluorescent probes 3b and 6. Results are
summarized in Table 3, with competition binding curves
for HU-308 and SR144528 obtained with probe 3b presented
in Figure 3D. Of note, Ki values obtained in this manner
agree with previously published benchmark values based on
radioligand binding assays.19 Furthermore, the same exper-
imental setup also allowed for successful determination of
kinetic binding parameters of HU-308 and SR144528. Data
obtained with 3b in competitive association experiments are
presented in Figure 3E, F, and the observed binding
parameters are summarized in Table 3. The determined
kinetic rate constants are in good agreement with literature
data derived using a CB2R-selective radioligand.
54 As
compared to HU-308, the higher affinity of SR144528 to
hCB2R is driven by a faster on-rate, with otherwise equivalent
off-rates.
To the best of our knowledge, this work is the first study
of ligand binding kinetics for CB2R-specific ligands
determined by TR-FRET. Fluorescent probes 3b and 6 are
Figure 3. TR-FRET-based fluorescent probe characterization (A−C) and determination of affinities and binding kinetics of CB2R ligands (D−
F). (A) Observed association of 3b to hCB2R. (B) Observed association rate, kobs, increases linearly with 3b concentration. (C) Saturation
analysis showing the binding of 3b to hCB2R. (D) Competition between 3b (100 nM) and increasing concentrations of CB2R-selective ligands
HU-308 and SR144528 for hCB2R. Probe 3b competitive association curves in the presence of HU-308 (E) and SR144528 (F). Kinetic and
equilibrium data were fitted to the equations described in the SI to calculate Kd, kon, and koff values for fluorescent and for unlabeled ligands.
Data are summarized in Tables 2 and 3, and are presented as mean ± SEM, N = 3−5.
Table 2. Binding Parameters of Fluorescent Probes to











3b 1.2 ± 0.1 0.04 ± 0.01 35 ± 7 36 ± 4
6 1.9 ± 0.5 0.03 ± 0.05 18 ± 3 13 ± 2
aData are presented as mean ± SEM, N = 3−5.




















3b 3.43 ± 1.34 0.15 ± 0.02 6.7 55 ± 15 23 ± 5 5.17 ± 1.26 0.12 ± 0.03 8.3 2.3 ± 0.3 1.5 ± 0.4
6 2.22 ± 0.84 0.10 ± 0.02 10 53 ± 12 153 ± 24 4.11 ± 1.28 0.12 ± 0.04 8.3 3.1 ± 0.3 4.9 ± 1.2
aData are presented as mean ± SEM, N = 3.
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attractive alternatives to radioligands for the study of binding
kinetics and affinities of unlabeled ligands to hCB2R, and they
are promising for HTS applications.
CB2R Specificity in Living CHO, Human, and Murine
Cells: FACS Studies. We set out to investigate the
specificity of the fluorescent probes by flow cytometry. This
included CHO cells overexpressing hCB2R, mCB2R, or
hCB1R along with wild-type CHO cells, which were
incubated with fluorescent probes at varying concentrations.
Notably, no negative effect on cell viability was observed at
probe concentrations up to 10 μM.
In subsequent FACS analyses, cells expressing hCB2R or
mCB2R treated with probes 3b, 4, and 5 showed increased
mean fluorescence intensity compared to cells expressing
hCB1R, as well as wild-type cells. Alexa488 probe 5
performed particularly well, and it specifically labeled CHO
cells expressing both mCB2R and hCB2R over a broad
concentration range of 0.12−10 μM (Figure 4A). Probe 3b
also specifically labeled cells expressing hCB2R or mCB2R,
and the increased fluorescence signal was statistically
significant at 3b concentrations >3.33 μM (p < 0.005, also
see SI Figure S7).67
Additionally, Alexa647 probe 4 showed significant increase
of fluorescence intensity for cells expressing hCB2R over a
concentration range of 0.37−10 μM (see SI Figure S7). It is
interesting to note that the performance of 4 in FACS is
somewhat at odds with its Ki value of 2.57 μM. We speculate
that two factors are responsible: (1) high fluorescence
intensity of Alexa647 and (2) minimal nonspecific binding
by the highly charged dye, as noted previously.68 Nonspecific
membrane binding is a major concern in commonly
employed CB2R ligands, which most often are highly
lipophilic in nature. Consequently, additional experiments
were performed to investigate the specificity of our
fluorescent probes. In particular, we examined whether pre-
incubation of cells with CB2R agonist JWH133 and inverse
agonist RO685122869 prior to FACS analysis interferes with
fluoroprobe binding. Both CB2R ligands competed with
probe 3b in a concentration-dependent fashion, supporting its
high target specificity (see SI Figure S7). Similarly, they
efficiently displaced Alexa488 probe 5 (Figure 4B) as well as
Alexa647 probe 4 (see SI Figure S7). To the best of our
knowledge, these data in flow cytometry represent the first
successful ligand displacement experiments of CB2R fluo-
rescent probes by validated CB2R ligands.
We subsequently set out to investigate the specificity of the
fluorescent probes in a living, clinically relevant, human cell
line. Probe 3b successfully labeled activated microglial cells
from 5xFAD mice. These mice recapitulate phenotypes
related to Alzheimer’s disease (AD) such as amyloid plaques
and increased expression of mCB2R in the CNS.
70 The use of
microglia derived from CB2R knockout (5xFAD/CB2KO)
71
mice led to significantly weaker labeling in flow cytometry,
which corroborates the CB2R specificity of 3b in this murine
AD model (Figure 5).
Real-Time Receptor Visualization in Living Cells:
Confocal Fluorescence Microscopy Studies. Based on
the high CB2R specificity of the fluorescent probes in FACS,
the suitability of 3b to visualize cell-surface CB2R was
assessed by real-time confocal microscopy. Exposure of CHO
cells overexpressing hCB2R to 3b resulted in distinct time-
and concentration-dependent labeling of the cell membrane.
Labeling with 0.2 μM 3b was detectable within 5 min and
increased progressively over time, reaching a steady-state
plateau after 8 min, and then remained unchanged, without
evidence of internalization, for up to 10 min (Figure 6A, also
see SI Video 1).
Of note, 3b was only weakly fluorescent in aqueous media,
allowing bright labeling of the cell membrane even in the
continued presence of the probe in culture medium. As a
control, at concentrations up to 0.6 μM, 3b did not produce
membrane labeling of CHO cells overexpressing hCB1R,
demonstrating the high specificity of this ligand for hCB2R as
Figure 4. (A) FACS analysis of cells incubated with 5 at varying
concentrations. MFI = mean fluorescence intensity. Representative
fluorescence intensity histograms of cells incubated with 0.37 μM 5.
Mean ± SEM, two-way ANOVA followed by Bonferroni post hoc
analysis, *p < 0.05; **p < 0.01; ***p < 0.005, N = 4−5. (B) FACS
analysis of cells pretreated with 10 μM of competitor ligands and
subsequently stained with varying concentrations of 5. Mean ±
SEM, two-way ANOVA followed by Bonferroni post hoc analysis,
*p < 0.05; **p < 0.01; ***p < 0.005, N = 3−5.
Figure 5. Fluoroprobe 3b specifically labels mCB2R on activated
microglial cells from AD mice (5xFAD). Shown is the percentage of
microglial cells positive for 3b. *p < 0.05 (two-way ANOVA
followed by Tukey’s post hoc analysis was performed after log
transformation of the fluorescence signal, N = 4−12).
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well as its particularly low nonspecific binding (Figure 6B;
also see SI Video 2).72 Image acquisition at higher
magnification and resolution was performed at the end of
the recording session. After 10 min of probe administration,
cell staining remained predominantly associated with the
plasma membrane (Figure 6C).73 However, after 30 min a
high number of small spots was observed on the cytoplasmic
side of the cell membrane as well as throughout the
cytoplasm, suggesting agonist-mediated endocytosis (Figure
6D). Consistently, 3b-induced internalization of hCB2R was
almost completely blocked in the presence of endocytosis
inhibitors (see SI Figure S8). Incidentally, these findings
confirmed that 3b, which exhibited a Peff of 0.4 cm/s·10
−6 in
PAMPA assay,74 is poorly membrane-permeant.75 Conse-
quently, 3b is suitable for specifically labeling hCB2R on the
cell surface for longer periods with minimal interference of
agonist-mediated internalization.
Having established its suitability in cells overexpressing
hCB2R, we also investigated the potential of 3b for primary,
non-transfected cells expressing the receptor at native levels.
In this context, 3b brightly labeled mouse splenocytes (Figure
7B) and human macrophages (Figure 7E) in a time-
dependent manner. In the presence of CB2R-specific agonist
JWH-133, drastic reduction of fluorescent labeling confirmed
CB2R specificity (Figure 7C,E and SI Videos 3−7). To the
best of our knowledge, such specificity in living cells
expressing CB2R endogenously is unprecedented for CB2R
fluorescent probes, underscoring the (pre-)clinical promise of
this probe. Collectively, these data demonstrate that DY-
480XL probe 3b is ideally suited for membrane-bound CB2R
Figure 6. Confocal fluorescence microscopy with CHO cells. Different frames from time-lapse confocal microscopy of cells co-stained with 3b
(red) and Hoechst 33342 (cyan, nucleus counter stain). (A) CHO-hCB2R cells incubated with 0.2 μM 3b at 1, 4, 6, 8, and 10 min; at each
time point, a region of interest (white strip-like curve shown in the insets) was drawn around the plasma membrane of cells (N = 6 for each
field). The changes in normalized fluorescence intensity were estimated over time (Fiji software), leading to an association curve. The data on
the curve represent the mean ± SD of at least three independent experiments. (B) CHO-hCB1R cells incubated with 0.2 μM 3b at 4, 8, and 10
min. See SI Videos 1 and 2 for animated views. Airyscan high-resolution imaging of hCB2R-overexpressing CHO cells incubated for either (C)
10 min or (D) 30 min with 0.2 μM 3b. Cells were optically sectioned using confocal laser-scanning microscopy equipped with an Airyscan
detector. (C) In the first 10 min, 3b staining was localized in the plasma membranes of CHO-hCB2R cells. (D) After 30 min, brighter and
increased number of vesicles, reminiscent of early endosomes, appeared below the plasma membrane and within the cytosol. Images are
representative of three independent experiments.
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real-time imaging with exceedingly low levels of nonspecific
binding.
■ CONCLUSION
A series of CB2R-selective fluorescent probes was synthesized,
characterized, and cross-validated in multiple laboratories, in
order to maximize the chance for successful translation of
preclinical applications. Our collaborative efforts led to
identification of reliable tools for flow cytometry and time-
resolved confocal microscopy with living human and murine
cells expressing CB2R. Moreover, evaluation of equilibrium
and kinetic binding parameters was performed in a novel TR-
FRET-based assay, which is amenable to high-throughput
screening. Probes bearing DY-480XL (3b), Alexa488 (5), and
AttoThio12 (6) dyes emerged as the most promising in
terms of in vitro pharmacology, showing nanomolar affinity to
hCB2R and good to excellent selectivity over hCB1R (hKi
ratios of 113, >37, and 228, respectively). Probes 3b and 6
were used for determination of Ki values and evaluation of
ligand binding kinetics of competing ligands by TR-FRET,
and thus they can be used as alternatives to radioligands. Our
probes allow detection and monitoring of CB2R in cells
which express the receptor endogenously, which is otherwise
not possible with current antibody technology. Probes 3b, 4,
and 5 specifically labeled mouse and human CB2R-positive
cell populations over a broad concentration range in FACS
analysis. Target specificity was established by the first report
of successful competition experiments with well-known CB2R
ligands (agonist and inverse agonist). Importantly, 3b could
be applied to the detection of endogenous CB2R levels such
as mCB2R on activated AD mouse microglia. Lastly, 3b was
successfully utilized to label and monitor live cells over-
expressing hCB2R by real-time confocal fluorescence
microscopy over prolonged time with minimal internalization.
mCB2R on mouse splenocytes and hCB2R on macrophages
were labeled by probe 3b, and specificity was established by
successful competition experiments with unlabeled agonist.
These findings highlight the translational promise of these
probes, as well as their potential for direct receptor detection,
a long sought-after goal for which so far no reliable tools
have been available. Consequently, 3b is a privileged
fluorescent probe for visualizing both human and murine
living cells expressing CB2R endogenously, and it may help
answer fundamental questions concerning CB2R expression in
health and disease.
Considering the wealth of questions regarding CB2R
expression and function in so many different cells and
tissues, it is likely that a single fluorescent probe will not
meet the requirements of any given experiment. In that
regard, amine platform 1 was shown to be privileged for the
preparation of a collection of fluorescent ligands specifically
targeting CB2R. Hence, 1 should serve as linchpin for
additional probes with bespoke pharmacological and photo-
physical properties. We believe the probes described herein
are valuable research tools for practitioners in the field. They
should find widespread use to foster better understanding of
CB2R in health and disease and to ultimately unlock the
receptor’s therapeutic potential.
Figure 7. Confocal microscopy with primary cells expressing CB2R endogenously. Confocal microscopy frames that show labeling of CB2R with
3b at 10 min in murine splenocytes and human macrophages. Murine splenocytes incubated for 10 min with (A) vehicle, (B) 0.4 μM 3b alone,
or (C) 0.4 μM 3b in the presence of 4 μM known CB2R agonist JWH-133 as competitor. Human macrophages for 10 min with (D) 0.6 μM 3b
alone or (E) 0.6 μM 3b in the presence of 4 μM JWH-133. Pretreatment with Hoechst 33342 (cyan) effected nuclear counter-staining.
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Video 1, time-lapse video of CHO-hCB1R cells labeled
with 0.2 μM 3b for 10 min (AVI)
Video 2, time-lapse video of CHO-hCB2R cells labeled
with 0.2 μM 3b for 10 min (AVI)
Video 3, time-lapse video of murine splenocytes
incubated with 0.05% DMSO (vehicle) for 10 min to
assess video background (AVI)
Video 4, time-lapse video of murine splenocytes labeled
with 0.4 μM 3b for 10 min (AVI)
Video 5, time-lapse video of murine splenocytes labeled
with 0.4 μM 3b in the presence of 4 μM JWH-133 for
10 min (AVI)
Video 6, time-lapse video of human macrophages
labeled with 0.6 μM 3b for 10 min (AVI)
Video 7, time-lapse video of human macrophages
labeled with 0.6 μM 3b in the presence of 4 μM JWH-
133 for 10 min (AVI)
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